ACCB Biotech

Beijing ACCB Biotech is focused on the R&D of cancer detection methods through the application of molecular biology technologies.

Beijing ACCB Biotech Ltd. (雅康博生物) is focused on the research and development of cancer detection methods through the application of molecular biology technologies. Based on the concept of personalized therapy, the company provides detection services that include early-cancer screening, drug selection, effect tracking, prognostic evaluation, transfer and recurrence monitoring, and other testing services. ACCB Biotech’s product series include EnzymAct, Baikangan, Gene 21 of Breast Cancer, automated workstation for nucleic acid extraction, and more. The company now has production, research and development, and service facilities of more than 3,000 square meters, and its cleanliness attains the criteria of 10,000 grades. In June, 2009, EnzymAct was successfully approved by the State Food and Drug Administration.